RNAi Therapeutics News and Research

RSS
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other anti-sense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression.
Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Key mechanisms for delivery of LNP-encapsulated siRNAs to the liver

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Pfizer presents data on in vivo activity of PF-04523655 siRNA drug candidate at ARVO annual meeting

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Alnylam Pharmaceuticals reports consolidated financial results for first quarter 2010

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Quark to present poster on predicting risk of DGF following machine perfusion of renal transplants at ATC 2010

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Biotherapeutics presents new data on RNAi technologies at Cell Culture Engineering XII

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Alnylam Pharmaceuticals announces EPO intent to grant notification for patent series covering RNAi therapeutics

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Alnylam Pharmaceuticals publishes encouraging results from Phase II GEMINI study in PNAS

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Novartis exercises current right to purchase 55,223 unregistered shares of Alnylam's common stock

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Silence Therapeutics, AstraZeneca announce one-year extension of ongoing siRNA delivery collaboration

Silence Therapeutics, AstraZeneca announce one-year extension of ongoing siRNA delivery collaboration

Silence Therapeutics reorganizes resources following Intradigm merger

Silence Therapeutics reorganizes resources following Intradigm merger

USPTO allows Alnylam Pharmaceuticals' new claims from Woppmann et al. patent series

USPTO allows Alnylam Pharmaceuticals' new claims from Woppmann et al. patent series

RXi Pharmaceuticals reports net loss of 28% for 2009

RXi Pharmaceuticals reports net loss of 28% for 2009

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

Dicerna Pharmaceuticals, Ipsen announce collaboration in DsiRNA research and peptide engineering

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

RXi Pharmaceuticals to present advances in RNAi therapeutics at 3rd International Scar Club Meeting

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Calando Pharmaceuticals demonstrates first targeted siRNA-containing nanoparticle delivery to tumors

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia